PIK3CA and cervical carcinoma: Similar findings have also been obtained from one deliberate investigation [78] conducted in cervical squamous cell carcinoma (CESC), where PIK3CA-mutant cervical cancer cells were more sensitive to the combination of BYL719 and cisplatin in vivo.